AngioDynamics (NASDAQ:ANGO) released its quarterly earnings data on Friday. The medical instruments supplier reported $0.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.01, MarketWatch Earnings reports. The business had revenue of $91.50 million for the quarter, compared to the consensus estimate of $89.24 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The company’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 earnings per share. AngioDynamics updated its FY 2019 guidance to $0.82-0.86 EPS and its FY19 guidance to $0.82-0.86 EPS.
NASDAQ ANGO opened at $21.52 on Friday. The stock has a market cap of $747.26 million, a price-to-earnings ratio of 29.08 and a beta of 0.74. AngioDynamics has a 52 week low of $15.26 and a 52 week high of $24.49. The company has a current ratio of 2.64, a quick ratio of 1.55 and a debt-to-equity ratio of 0.16.
ANGO has been the topic of several recent research reports. BidaskClub raised shares of AngioDynamics from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 8th. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. AngioDynamics presently has a consensus rating of “Buy” and an average price target of $18.44.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.wkrb13.com/2019/01/06/angiodynamics-ango-issues-quarterly-earnings-results.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Further Reading: Market Capitalization and Individual Investors
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.